Here are the The antidiabetic effects of konjac glucomannan on the clinical outcomes of patients with T2DM: A systematic review journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
The antidiabetic effects of konjac glucomannan properties, the antidiabetic effects of konjac glucomannan gnc, the antidiabetic agents, the antidiabetic definition, the antidiabetic side, the antidiabetic medications, the effects of climate change.
The antidiabetic effects of konjac glucomannan on the clinical outcomes of patients with T2DM: A systematic review
Context: Type-2 diabetes mellitus (T2DM) is a complex metabolic disorder that causes insulin resistance in the body. On the other hand, konjac glucomannan (KGM) is known to have beneficial effects on diabetes by reducing HbA1c, postprandial glucose, and insulin resistance. However, only a few studies have been conducted in individuals with T2DM or glucose intolerance. Aims: To evaluate the effectiveness of konjac glucomannan on the clinical outcomes of T2DM patients treated with oral antidiabetic drugs (OAD) and/or insulin.
Methods: A systematic study was carried out based on the PRISMA protocol by synthesizing trials in T2DM patients treated with OAD and/or insulin. Articles were searched from Science Direct, PubMed, Cochrane Library, and ProQuest databases. The primary outcomes studied were glycated hemoglobin (HbA1c), postprandial glucose (PPG), homeostatic model assessment (HOMA-IR), and fasting serum insulin (FSI). Articles meeting the eligibility criteria were assessed for risk of bias using the Jadad's scale.
Results: A total of 129 participants were included from six trials meeting the eligibility criteria, with ages ranging from 25-75 years and duration of KGM intervention lasting from 2-12 weeks. Two studies had a low risk of bias based on Jadad's score analysis. Significant reductions in HbA1c, PPG, and fasting blood glucose (FBG) were reported in four studies, while HOMA-IR reduction was found in one study. The different types of KGM and duration of administration might have different influences on the effectiveness of glucomannan in the studied outcomes.
Conclusion: Konjac glucomannan can reduce PPG, FBG, HbA1c, and HOMA-IR in T2DM patients on OAD and/or insulin. © 2024 Journal of Pharmacy & Pharmacognosy Research.
Authors : Febrinasari R.P.; Rizqia P.N.; Hikmayani N.H.
Source : Academic Association of Pharmaceutical Sciences from Antofagasta (ASOCIFA)
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.56499/jppres23.1774_12.s1.96 |
| ISSN | 07194250 |
| Volume | 12 |
You can download the article here
If You have any problem, contact us here